Skip to search boxSkip to navigationSkip to main content

Nicotinic acetylcholine receptor ligands, cognitive function, and preclinical approaches to drug discovery

*Corresponding author for this work
Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Interest in nicotinic acetylcholine receptor (nAChR) ligands as potential therapeutic agents for cognitive disorders began more than 30 years ago when it was first demonstrated that the tobacco alkaloid nicotine could improve cognitive function in nicotine-deprived smokers as well as nonsmokers. Numerous animal and human studies now indicate that nicotine and a variety of nAChR ligands have the potential to improve multiple domains of cognition including attention, spatial learning, working memory, recognition memory, and executive function. The purpose of this review is to (1) discuss several pharmacologic strategies that have been developed to enhance nAChR activity (eg, agonist, partial agonist, and positive allosteric modulator) and improve cognitive function, (2) provide a brief overview of some of the more common rodent behavioral tasks with established translational validity that have been used to evaluate nAChR ligands for effects on cognitive function, and (3) briefly discuss some of the topics of debate regarding the development of optimal therapeutic strategies using nAChR ligands. Because of their densities in the mammalian brain and the amount of literature available, the review primarily focuses on ligands of the high-affinity α4β2* nAChR (“*” indicates the possible presence of additional subunits in the complex) and the low-affinity α7 nAChR. The behavioral task discussion focuses on representative methods that have been designed to model specific domains of cognition that are relevant to human neuropsychiatric disorders and often evaluated in human clinical trials. Implications: The preclinical literature continues to grow in support of the development of nAChR ligands for a variety of illnesses that affect humans. However, to date, no new nAChR ligand has been approved for any condition other than nicotine dependence. As discussed in this review, the studies conducted to date provide the impetus for continuing efforts to develop new nAChR strategies (ie, beyond simple agonist and partial agonist approaches) as well as to refine current behavioral strategies and create new animal models to address translational gaps in the drug discovery process.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 383-394 (12 pages)

Journal (Volume, Issue Number)

Nicotine and Tobacco Research (Volume 21, Issue 3)

Publication milestones

  • Published - 02/18/2019

Publication status

Published - 02/18/2019

ISSN

1462-2203

Publication IDs

  • Scopus: 85062105618
  • PubMed: 30137518

Publication metrics

Metrics

SciVal
citations
11
SciVal
FWCI
1.59
SciVal
Author count
2
SciVal
Paper percentile
90
SciVal
Top percentile
10
Fractional count
2
Fractional count
1
Fractional count
2
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
65
Citation count
46
Mentions
3

Funding Details

The corresponding author's laboratories and/or salary are supported in part by the following funding sources: National Institutes of Health (grants MH097695, MH083317, and NS099455), Institut de Recherches Servier, and Prime Behavior Testing Laboratories, Evans, Georgia.
FundersFunding numbers
NIH
MH083317, NS099455, MH097695
Servier
-